Integrated analysis of the phase 3 VALOR trial and open-label extension (108 adults with SOD1-ALS): over 148 weeks, early vs delayed tofersen start was associated with numerically less decline in ALSFRS-R (-9.9 vs -13.5) and slow vital capacity.
RCTn = 108
Miller et al. Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis